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Chemokines attract leukocytes to sites of infection in a G protein-coupled receptor (GPCR) and 
glycosaminoglycan (GAG) dependent manner. Therefore, chemokines are crucial molecules for proper 
functioning of our antimicrobial defense mechanisms. In addition, some chemokines have GPCR-
independent defensin-like antimicrobial activities against bacteria and fungi. Recently, high affinity for 
GAGs has been reported for the positively charged COOH-terminal region of the chemokine CXCL9. In 
addition to CXCL9, also CXCL12γ has such a positively charged COOH-terminal region with about 50 % 
positively charged amino acids. In this report, we compared the affinity of COOH-terminal peptides of 
CXCL9 and CXCL12γ for GAGs and KD values in the low nM range were detected. Several enveloped 
viruses such as herpesviruses, hepatitis viruses, human immunodeficiency virus (HIV), dengue virus 
(DENV), etc. are known to bind to GAGs such as the negatively charged heparan sulfate (HS). In this 
way GAGs are important for the initial contacts between viruses and host cells and for the infection of 
the cell. Thus, inhibiting the virus-cell interactions, by blocking GAG-binding sites on the host cell, might 
be a way to target multiple virus families and resistant strains. This article reports that the COOH-
terminal peptides of CXCL9 and CXCL12γ have antiviral activity against DENV serotype 2, clinical and 
laboratory strains of herpes simplex virus (HSV)-1 and respiratory syncytial virus (RSV). Moreover, we 
show that CXCL9(74-103) competes with DENV envelope protein domain III for binding to heparin. 
These short chemokine-derived peptides may be lead molecules for the development of novel antiviral 
agents. 
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The emergence of drug-resistant viruses and the absence of vaccination strategies for several viruses 
evokes the need for novel classes of antivirals [1;2]. Previously, antiviral drugs targeting the binding 
and entry of viruses such as human immunodeficiency virus (HIV), hepatitis C virus (HCV) and herpes 
simplex viruses type 1 and 2 (HSV-1 and -2) were developed and approved or are currently undergoing 
clinical trials [3-5]. Blocking the viral infection at this early stage is less toxic with less side effects 
compared to chemotherapeutics affecting the viral multiplication cycle that are currently used. 
Examples of binding and entry inhibitors are maraviroc [6;7], a chemokine receptor antagonist 
preventing the entry of HIV, and carbohydrate-binding agents that bind to glycoproteins on the virus 
surface thereby preventing infection with dengue virus (DENV) [8]. DENV is one of the most important 
emerging viruses in tropical and subtropical countries with 2.5 billion people at risk to get infected and 
every year more than 50 million clinical cases of DENV infections [9]. Further, it was shown that several 
viruses such as HSV-1, hepatitis B virus (HBV), HIV-1, DENV, vaccinia virus (VV) and adenovirus (ADV) 
bind to glycosaminoglycans (GAGs) for entering and infecting the host cell [10-19]. GAGs are linear 
polysaccharides consisting of repeating disaccharide subunits which can be divided into six classes: 
heparin, heparan sulfate (HS), chondroitin sulfate, dermatan sulfate, keratan sulfate and hyaluronic 
acid [20]. Several interactions of GAGs with proteins have already been described for growth factors 
(e.g. fibroblast growth factor-1 and -2), adhesion molecules, enzymes and chemokines (e.g. CXCL8 and 
CXCL4) [21;22]. As a result of these interactions, GAGs participate in many physiological and 
pathological processes such as cell growth, signal transduction, cell adhesion, inflammation, cancer 
and microbial infection [23-25]. HS, consisting of alternating glucosamine and uronic acids residues 
that can be N-acetylated or N-sulfated, is ubiquitously present on most mammalian cells and tissues 
and is expressed as heparan sulfate proteoglycans (HSPGs) whereby GAGs are covalently attached to 
a central core protein. Because of its high degree of sulfation, HS contains a considerable number of 
negatively charged groups which can interact with viral proteins that carry positive charges. In this way 
HS is important for the initial contacts between viruses and host cells. However, not only the 
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nonspecific ionic interactions are important for the binding of viruses to HS, this binding is suggested 
to be more complex in several ways. First, it has been suggested that cell surface HS could serve as a 
specific binding site for several viruses such as DENV, HSV-1 and HIV-1 [12;26-28]. Second, saccharide 
structures of HS have different activities in promoting viral infections. For example, for the binding of 
HSV-1 to cells, highly sulfated HS interacts with viral glycoproteins C and B [29;30]. Subsequently, 
specific 3-O-sulfated HS interacts with viral glycoprotein D which is essential for entry of the virus 
[26;31]. 
Although it has already been shown that suramin, a substance that inhibits binding to HS on the 
membrane of hepatocytes, blocks entry of HBV, hepatitis D virus (HDV) and HIV in vitro, no antiviral 
drugs targeting this interaction have yet been developed [32]. However, more recently, a new class of 
synthetic peptides with a sequence based on the lipopolysaccharide (LPS)-binding domain of the 
Limulus anti-LPS factor was shown to block attachment and entry of human pathogenic viruses [33]. 
These synthetic anti-LPS peptides bind to HS on the cell surface of the host cells and inhibit infection 
with a variety of enveloped viruses such as HIV-1, HSV-1 and HSV-2, HBV and HCV. In addition, novel 
HS-binding peptides that block entry of herpesviruses were synthesized [34]. Thus, inhibiting the virus-
cell interactions, by blocking GAG binding sites on the host cell, is a way to target multiple virus types 
and resistant virus strains. 
Chemokines are a class of leukocyte chemotactic cytokines which exert their function through binding 
both to GAGs and to G protein-coupled receptors (GPCRs) and GAG binding is indispensable for the 
in vivo function of chemokines [35-42]. Chemokines can be divided into four groups based on the 
position of two conserved NH2-terminal cysteine residues. The CC chemokines have two adjacent 
cysteine residues, whereas in CXC and CX3C chemokines these residues are separated by one or three 
amino acids (X), respectively [43]. In the C chemokine subfamily only one of the two NH2-terminal 
cysteine residues is conserved. Recently, COOH-terminal peptides of the chemokine CXCL9 or 
monokine induced by interferon-γ (MIG) were described as potent GAG binding peptides [44]. By 
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competing with CXCL8 for the binding to GAGs, these peptides could inhibit the in vivo chemotactic 
activity of CXCL8. These peptides could not only inhibit CXCL8-induced neutrophil extravasation but 
also monosodium urate crystal-induced gout in mice. This implies that in vivo not only the activity of 
CXCL8, but the activity of multiple mouse chemotactic factors important in monosodium urate crystal-
induced gout could be inhibited. In addition to CXCL9, also CXCL12γ or stromal cell-derived factor-1γ 
(SDF-1γ) has a COOH-terminal region with many positively charged amino acids [45]. Therefore, the 
GAG binding affinity of COOH-terminal peptides of CXCL9 and CXCL12γ, which are remarkably long and 
basic with 50 % of the amino acids being positively charged, were compared in this study and their 
potential to inhibit infection of cells with several viruses such as DENV, HSV-1, HSV-2 and respiratory 
syncytial virus (RSV) was evaluated. 
2. Materials and Methods 
2.1. Cells and viruses 
Chinese hamster ovary (CHO) cells were a gift from M. Parmentier (ULB, Brussels, Belgium) and were 
cultured in Ham’s F-12 medium (with L-glutamine; Lonza, Verviers, Belgium) supplemented with 10 % 
fetal calf serum (FCS) and 0.8 µg/ml G418 (Geneticin®; Life technologies). To inhibit sulfation of cellular 
GAGs, CHO cells were cultured in the presence of 100 mM sodium chlorate (NaClO3; Sigma Aldrich, St. 
Louis, MO) for 24 h [44]. Human embryonic lung (HEL) and human cervical carcinoma (HeLa) cells were 
grown in modified Eagle’s medium Rega 3 supplemented with 8 % FCS, 2 mM L-glutamine and 1.5 % 
sodium bicarbonate (Gibco, Carlsbad, CA, USA). The human microvascular endothelial cell line HMEC-1 
was obtained from the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) and was 
grown in microvascular endothelial cell growth medium (Lonza) [46]. All cell types were maintained in 
a humidified 5 % CO2 incubator at 37°C. 
The peptides were tested against the following viruses: HSV-1 KOS strain, HSV-2 G strain, VV Lederle 
strain, ADV type 2 (ADV-2), RSV, and DENV serotype 2 (DENV-2). Also several clinical isolates of wild-
type HSV-1 (RV-852, RV-849, RV-832, RV-830) and wild-type HSV-2 (RV-795, RV-723, RV-720, RV-636) 
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from virus-infected individuals in Belgium were used. All viruses were obtained and used approved by 
the Belgian equivalent of IRB (Departement Leefmilieu, Natuur en Energie, protocol SBB 219 
2011/0011) and the Biosafety Committee at KU Leuven. Antiviral assays were performed in infection 
medium, i.e. modified Eagle’s medium Rega 3 supplemented with 2 % FCS, 2 mM L-glutamine and 1.5 
% sodium bicarbonate for HEL and HeLa cells, and microvascular endothelial cell growth medium for 
HMEC-1 cells. 
2.2. Solid phase synthesis of COOH-terminal peptides 
COOH-terminal peptides of CXCL9 and CXCL12γ were chemically synthesized using fluorenyl 
methoxycarbonyl (Fmoc) chemistry using an Activo-P11 automated synthesizer (Activotec, Cambridge, 
UK), as previously described [47]. In brief, peptides were synthesized based on solid-phase synthesis 
conducting cycles of (1) deprotection, (2) activation and (3) coupling. The α-carboxyl group of the 
COOH-terminal amino acid was attached to a solid support, namely HMP-resin (4-hydroxymethyl-
phenoxy-methyl-polystyrene, cross-linked by 1 % divinylbenzene). After each coupling step the 
remaining free α-amino acids were capped. Part of the material was site-specifically biotinylated or 
fluorescently labeled at the NH2-terminus using biotin-p-nitrophenyl ester (Novabiochem, Darmstadt, 
Germany) or 5(6)-carboxytetramethylrhodamine (TAMRA; Merck Millipore, Darmstadt, Germany) 
applying the standard amino acid coupling chemistry. After removal of the resin beads and side chain 
protection groups, intact synthetic peptides were separated from incompletely synthesized by-
products by reversed-phase high performance liquid chromatography (RP-HPLC) on a Source 5-RPC 
column (4.6 x 150 mm; GE Healthcare, Little Chalfont, UK) applying an acetonitrile gradient in 0.1 % 
(v/v) trifluoroacetic acid (Biosolve, Valkenswaard, The Netherlands). A part of the column effluent (0.7 
%) was split for analysis to an Amazon SL ion trap mass spectrometer (Bruker, Bremen, Germany) and 
fractions containing pure peptide were pooled and lyophilized. To determine the protein 
concentration, the weight of the dry peptide powder was measured on an analytical scale before 
dissolving it in ultrapure water. 
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2.3. Binding of COOH-terminal peptides to cellular GAGs and competition with CXCL8 
Binding of biotinylated peptides to CHO cells was assessed by flow cytometry as recently described 
[48]. Briefly, cells were detached by phosphate-buffered saline (PBS) containing 0.02 % 
ethylenediaminetetraacetic acid (EDTA; Sigma Aldrich). Subsequently, 2.5x105 cells were incubated 
with NH2-terminally biotinylated peptides for 1 h on ice, washed and incubated for 30 min on ice in the 
dark with streptavidin-allophycocyanin [1/150; BD Biosciences, San Jose, CA]. Finally, cells were 
washed with ice-cold assay buffer, fixed and analyzed by flow cytometry (FACSCalibur, BD Biosciences).  
2.4. Flow cytometric analysis of HS expression 
To confirm inhibition of sulfation of cellular GAGs after NaClO3 treatment, part of the CHO cells were 
stained with a mouse monoclonal anti-human HS antibody (Immunosource, Schilde, Belgium), washed, 
incubated with a secondary phycoerythrin-labeled goat anti-mouse antibody (1/150; BD Biosciences) 
and analyzed by flow cytometry. HEL and Hela cells were stained and analyzed in a similar way. 
Statistical analyses were performed using the Mann-Whitney U-test. 
2.5. Biotinylation of heparin and surface plasmon resonance (SPR) analysis 
1 mM of heparin (Sigma Aldrich) and 10 mM biotinamidohexanoic acid hydrazide (Sigma Aldrich) were 
mixed in PBS at room temperature for 24 h. Afterwards, the mixture was dialyzed against PBS to 
remove unreacted biotin. 
SPR was used to evaluate binding between synthetic CXCL9- and CXCL12γ-derived peptides and 
heparin. Neutravidin (Perbio science bvba, Erembodegem, Belgium) was covalently immobilized on 
two flow cells of a Series S Sensor Chip CM4 in 10 mM sodium acetate, pH 5.5, using standard amine 
coupling chemistry, resulting in chip densities of 2000 RU. Next, biotinylated heparin was captured on 
the second flow cell at 76 RU. The first flow cell was left untreated and was used as a control for non-
specific binding and refractive index changes. All interactions were performed at 24 °C on a Biacore 
T200 instrument (GE Healthcare, Uppsala, Sweden) in HBS-EP (10 mM HEPES, 150 mM NaCl, 3 mM 
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EDTA and 0.05 % surfactant P20; pH 7.4). Samples were injected for 2 min at a flow rate of 30 µl/min 
and the dissociation phase was followed for 5 min. Several buffer blanks were used for double 
referencing. The second sensor chip surface was regenerated with 1 M NaCl (30 sec) and stabilized for 
another 5 min. Binding affinities (KD) were derived from steady state analysis using the Biacore T200 
Evaluation Software 2.0. To evaluate competition between recombinant envelope (E) protein domain 
III of DENV-2 and the synthetic peptides for heparin binding the same sensor chip was used. The 
analytes, 400 nM of E protein domain III alone or premixed with a concentration range of the synthetic 
CXCL9- or CXCL12γ-derived peptides were injected for 2 min at a flow rate of 30 µl/min, followed by a 
dissociation phase of 2 min. The sensor chip surface was regenerated with 10 mM NaOH containing 1 
M NaCl. 
2.6. Antiviral and cytotoxicity assays 
HeLa and HEL cells were seeded in microtiter 96-well plates and grown to confluence. Confluent 
monolayers were inoculated with 100 CCID50 of virus (50 % cell culture infectious dose, 1 CCID50 being 
the amount of virus that infects 50 % of the cell culture) in the presence of serial dilutions of the 
synthetic peptides [49-51]. The antiviral activity was determined by the ability to inhibit the virus-
induced cytopathogenic effect in the different cell lines (HeLa cells for infection with RSV and HEL cells 
for infection with HSV-1, HSV-2, ADV-2 and VV). In addition, to investigate whether the peptide binds 
directly to the virus, HSV-1 (100x) was incubated with 100 µM CXCL9(74-103) for 30 min. Next, the 
mixture was diluted 100-fold to obtain an inactive peptide concentration and an active virus 
concentration and added to HEL cells. Viral cytopathogenicity was determined when it reached 100 % 
in the untreated cell control and antiviral activity was expressed as the EC50 value (effective 
concentration of peptide required to reduce virus-induced cytopathogenicity by 50 %). Inhibition of 
DENV-2 infection of HMEC-1 cells was evaluated in gelatin-coated 48-well plates. After an overnight 
incubation, confluent monolayers were infected with DENV-2 at a multiplicity of infection of 2 plaque 
forming units in the presence of different concentrations of the peptides. Cells were analyzed for DENV 
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infection by flow cytometry at 24 h after infection, as described previously [52]. The EC50 value was 
determined as the peptide concentration required to inhibit DENV-2 infection of HMEC-1 cells by 50 %.  
Potential cytotoxic effects of the compounds were evaluated in parallel by 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium method (MTS; Promega 
Corporation, Madison, WI). HeLa and HEL cells were seeded in 96-well plates and grown to confluence. 
Confluent monolayers were incubated with serial dilutions of the synthetic peptides. Next, medium 
was replaced by 100 µl of 0.02 % MTS in PBS and incubated for 2 h at 37 °C. The optical density was 
determined at 490 nm and the 50 % cytotoxic concentration (CC50; i.e. drug concentration needed to 
reduce the total cell number by 50 %) was calculated. 
2.7. Induction experiments and cytokine levels 
For the induction experiments, cells were seeded in microtiter 48-well plates and grown to confluence. 
Confluent monolayers were inoculated with RSV, HSV-1 or DENV-2, as described above, in the presence 
or absence of the synthetic peptides (25 µM). Furthermore, confluent monolayers were incubated with 
vehicle or peptides alone.  Supernatants were collected after 24 h and after 4 days for, respectively, 
infection with DENV-2 and infection with RSV or HSV-1 and kept at -20 °C for further use. The cytokine 
levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interferon-α (IFN-
α) and interferon-β (IFN-β) in the supernatants were measured using ELISA kits according to the 
manufacturer’s instructions. Human IL-1β, TNF-α and IL-6 were measured by a Duoset® sandwich ELISA 
(DuoSet® ELISA Development System, R&D Systems, Minneapolis, USA) and human IFN-α and IFN-β 
were measured by VeriKine-HS Human Interferon α or β Serum ELISA Kits (PBL Assay Science, NJ, USA).  
2.8. Caspase-1 activity assay 
Cells from induction experiments were lysed with buffer containing 20 mM HEPES, 100 mM NaCl, 10 
mM dithiothreitol (DTT), 100 µM phenylmethylsulfonyl fluoride (PMSF), 1 mM EDTA, 0.1 % CHAPS, 10 
% sucrose and 1 % Triton-X-100 (pH 7.2). The protein concentration of each sample was determined 
and equal amounts of lysate were incubated with 50 µM of acetyl-Tyr-Val-Ala-Asp-
10 
 
aminomethylcoumarin (Ac-YVAD-AMC; Enzo Life Sciences, Antwerp, Belgium) in 100 mM Tris (pH 7.2) 
at 37 °C. Fluorescence of the free AMC fluorophore was measured for 4-10 h at 10-min intervals by 
fluorometry (excitation and emission wavelengths of 340-360 nm and 440-460 nm).  
2.9. Immunocytochemistry 
HMEC-1 cells were seeded on gelatin-coated 8-well Millicell EZ slides (Merck Millipore). Confluent 
monolayers were infected with DENV-2 as described above in the presence or absence of 20 µM of 
TAMRA-labeled CXCL9(74-103). After 24h the cells were fixed in 2% paraformaldehyde and 
permeabilized with 0.1% Triton X-100. Nonspecific binding sites were blocked with 0.5% bovine serum 
albumin in PBS. The cells were incubated with a mouse anti-dengue virus type II monoclonal antibody, 
clone 3H5.1 (2.5 µg/ml; Merck Millipore) followed by an Alexa Fluor 488 goat anti-mouse antibody (4 
µg/ml; Molecular Probes).  Nuclei were stained with Hoechst 33342 (2 µg/ml; Molecular Probes). 
Fluorescent microscopic analysis was done with an Axiovert 200 M inverted microscope (Zeiss, 
Göttingen, Germany), using an EC Plan Apochromat 20x/0.8 objective. 
3. Results 
3.1. Synthesis and purification of COOH-terminal peptides 
CXCL9 contains 103 amino acids and plays a key role in the trafficking of activated T cells and natural 
killer (NK) cells [53-55]. The COOH-terminal region of CXCL9 is remarkably long (residues 74 till 103) 
and basic (with 50 % positively charged amino acids) in comparison with other chemokines (Figure 1). 
Also CXCL12γ, a splicing variant of CXCL12, has a characteristic 30 amino acid long COOH-terminal tail 
(residues 68 till 98), containing 18 basic residues. Therefore, COOH-terminal peptides of CXCL9 and 
CXCL12γ, i.e. CXCL9(74-103), CXCL9(86-103), CXCL9(79-103), CXCL9(74-93), CXCL9(74-86), 
CXCL12γ(68-98) and CXCL12γ(77-98) were synthesized and purified by RP-HPLC. In addition, 
NH2-terminally acetylated and COOH-terminally amidated CXCL9(74-103) and NH2-terminally 
site-specifically biotinylated or fluorescently labeled CXCL9(74-103) and CXCL12γ(68-98) were 
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produced (Figure 1). Their Mr was confirmed by ion trap mass spectrometry as exemplified by 
CXCL12γ(68-98) and biotinylated CXCL12γ(68-98) (Figure 2). 
3.2. Binding characteristics of COOH-terminal peptides to immobilized heparin 
Different viruses have been reported to use HSPGs as attachment/entry receptors on the surface of 
target cells. Therefore, compounds that competitively bind to HSPGs may block virus infection. To 
study the antiviral activity of the positively charged COOH-terminal CXCL9 and CXCL12γ peptides, the 
ability of the different peptides to bind heparin was first evaluated using surface plasmon resonance 
(SPR) analysis. Heparin was biotinylated as described in the materials and methods section and 
captured on immobilized neutravidin on a CM4 sensorchip. Kinetic analysis of the binding to heparin 
was performed by injecting increasing concentrations of the peptides over the heparin surface 
(Figure 3). The rising part of each curve (0-120 sec) corresponds to the association phase of the 
peptides to heparin, whereas the descending part (120-300 sec) represents the dissociation phase. The 
binding affinities (KD) were derived from steady state analysis using the Biacore T200 Evaluation 
Software (Table 1). These data indicate that the CXCL9(74-103) peptide binds to heparin with the 
highest affinity (KD=3.1 nM), whereas the acetyl-CXCL9(74-103)-amide peptide and CXCL9(74-93) bind 
with slightly lower but comparable affinity (KD=8.8 nM and KD=11 nM, respectively). This indicates that 
the ten COOH-terminal residues also play a role in the heparin binding affinity. In contrast, the 
CXCL9(79-103), CXCL9(86-103) and CXCL9(74-86) peptides showed lower or very weak affinity for 
heparin binding (KD=162 nM, KD=820 nM and KD=3558 nM, respectively), suggesting a major role for 
the GAG binding motif between Lys-85 and Lys-89 in CXCL9 for heparin binding. However, also the first 
GAG binding motif enhances the affinity for heparin. Both CXCL12γ derived peptides had high affinity 
for heparin. KD values of 8 and 18 nM were calculated for CXCL12γ(68-98) and CXCL12γ(77-98), 
respectively. 
3.3. Binding of CXCL9(74-103) and CXCL12y(68-98) to cellular GAGs  
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To determine the binding of the peptides to cellular GAGs, the two peptides with the lowest KD on the 
heparin-coated sensorchips, i.e. CXCL9(74-103) and CXCL12γ(68-98), were site-specifically biotinylated 
at the NH2-terminus and binding of the biotinylated peptides to CHO cells was evaluated by flow 
cytometric analysis. To ensure that binding was GAG-mediated, CHO cells were treated with NaClO3 to 
reduce the expression of cellular GAGs. Treatment of CHO cells resulted on average in 71.4 % reduction 
of HS expression, as an indication for the total GAG expression (data not shown). This reduction of HS 
expression is the result of the reduction in sulfation of HS. As seen in Figure 4A, CXCL12γ(68-98) bound 
dose-dependently to cellular GAGs on CHO cells. Remarkably, at lower concentrations, CXCL12γ(68-98) 
seemed to bind better to cellular GAGs than CXCL9(74-103), although it was not significant. Finally, 
treatment of the cells with NaClO3 significantly reduced the binding of CXCL12γ(68-98) to cellular GAGs 
(Figure 4B).  
3.4. Antiviral activity of the COOH-terminal peptides 
The high affinities of the positively charged COOH-terminal peptides for heparin indicate that they may 
compete with endogenous and exogenous (e.g. viral) HSPG ligands for binding to immobilized heparin 
and cellular HSPGs. As such, these peptides may interfere with the attachment step during viral 
infection, since HS has been shown to serve as an attachment receptor for a number of viruses. 
Therefore, the antiviral capacity of the peptides was evaluated against 6 different human viruses that 
have been reported to use HSPGs for their attachment to target cells. CXCL9(74-103), acetyl-
CXCL9(74-103)-amide, CXCL9(74-93) and both CXCL12γ peptides were found to exert antiviral activity 
against DENV-2 (EC50 values between 11 and 48 µM), HSV-1 (EC50 values between 9 and 59 µM) and 
RSV (EC50 values between 23 µM to 115 µM) (Table 2), without causing any cytotoxic effect (CC50 > 150 
µM) (data not shown). The CXCL9(79-103) peptide was found to exert antiviral activity against HSV-1 
(EC50 = 33.5 µM) and weakly against RSV (EC50 = 100 µM) and DENV-2 (no EC50 was reached). In general 
the CXCL9(74-103) peptide had the strongest antiviral activity, whereas CXCL9(86-103) and 
CXCL9(74-86) were unable to inhibit any of the viruses tested. The CXCL12γ peptides showed a 2- to 5-
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fold lower antiviral activity against DENV-2, HSV-1 and RSV, when compared to CXCL9(74-103). No 
significant or a very weak (no EC50 value reached at 100 µM) antiviral effect against HSV-2, VV and 
ADV-2 was observed for the peptides. In view of the striking difference in antiviral activity of the 
peptides against laboratory strains of HSV-1 and HSV-2, the antiviral activity of the peptides was tested 
against several clinical isolates of wild-type HSV-1 and HSV-2 from virus-infected individuals in Belgium. 
In these experiments the same trend was seen in that the peptides were more effective against HSV-
1 compared to HSV-2 (Figure 5), suggesting that HSV-1 and HSV-2 attach to the host cells in a different 
way. Again, CXCL9(74-103) and acetyl-CXCL9(74-103)-amide peptides had the strongest antiviral 
activity, whereas CXCL9(86-103) and CXCL9(74-86) were unable to inhibit both HSV-1 and HSV-2 
infection. Interestingly, dextran sulfate which also blocks attachment of the virus to the host cells was 
found to be more effective against HSV-2 than against HSV-1. This shows that there is indeed a 
difference in the infection of HEL cells with HSV-1 or HSV-2. No difference between anti-HSV-1 or anti-
HSV-2 activity was seen for acyclovir, an antiviral which is used to treat HSV infections and targets the 
viral DNA polymerase [56]. To investigate whether the peptides could also bind directly to the virus 
thereby inducing virucidal activity, 100-fold concentrated HSV-1 was pre-incubated with 100 µM 
CXCL9(74-103). After 100-fold dilution (to obtain an inactive peptide but an active virus concentration) 
and subsequent infection of the cells, no antiviral effect of the peptides was seen (data not shown).  
To further investigate the molecular details of anti-viral immunity from non-immune cells, including 
HEL, HeLa and HMEC-1 cells, cytokine levels of IL-6, TNF-α, IL-1β, IFN-α and IFN-β were measured in 
the presence or absence of CXCL9(74-103) and CXCL9(86-103). No effect of the peptides was seen on 
either virus-induced or spontaneous cytokine production (data not shown). Next, the activation of 
caspase-1 was evaluated using the fluorescent caspase substrate Ac-YVAD-AMC. Also no direct effect 
of the peptides on caspase-1 activation was seen on non-infected HEL cells (Figure 6A), HeLa cells 
(Figure 6B) and HMEC-1 cells (Figure 6C). Further, the expression of HS on HEL and HeLa cells was 
determined by flow cytometric analysis, but no significant difference in HS expression was observed 
(Figure 6D). Therefore, it can be concluded that differences in antiviral activity against different viruses 
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(on other cell types) are not caused by a difference in HS expression, but more likely by the dependence 
of the particular virus on a specific GAG for infection.  
3.5. The CXCL9(74-103) peptide competes with DENV envelope protein for binding to heparin 
Next, the anti-DENV activity of the CXCL9 or CXCL12γ peptides was studied in more detail. 
A dose-dependent inhibition of endothelial cell infection by DENV-2 was observed in the presence of 
increasing concentrations of the peptides (Figure 7A). CXCL9(74-103) showed the strongest anti-DENV 
activity with an EC50 of 11 µM, whereas the CXCL9(86-103) and CXCL9(74-86) peptide did not block the 
DENV infection of endothelial cells (EC50 > 100 µM). For the CXCL9(79-103) peptide some antiviral 
activity against DENV-2 was seen, but no EC50 value could be calculated. The COOH-terminal CXCL12γ 
peptides could also inhibit DENV infection with an EC50 of 22 µM to 48 µM. Next, the infectivity of 
DENV-2 in endothelial cells was visualized using immunocytochemistry (Figure 7B). This clearly showed 
that 20 µM of fluorescently labeled CXCL9(74-103) binds to endothelial cells thereby inhibiting the 
infection by DENV-2. The DENV virion can attach to endothelial cells by the interaction of its envelope 
(E) protein with cell surface-associated HS-containing proteoglycans. Indeed, domain III of the E 
protein contains two putative GAG binding sites, which are assumed to be involved in the interaction 
between the DENV E protein and HSPGs. Since the COOH-terminal chemokine-derived peptide 
CXCL9(74-103) bound with high affinity to GAGs, the binding of DENV E domain III to heparin was 
investigated by SPR in the absence or presence of CXCL9(74-103) or the low affinity heparin-binding 
peptide CXCL9(86-103). The SPR sensorgrams show binding of DENV E domain III (E DIII) to captured 
heparin on a neutravidin CM4 chip in the presence (blue curve) or absence (red curves) of different 
concentrations of the CXCL9 peptides (Figure 8). Binding of the CXCL9-derived peptides in the absence 
of DENV E DIII is shown as a green line. When CXCL9(74-103) and DENV E DIII were applied at equimolar 
concentrations (400 nM) over the heparin surface, the binding curve coincides with that of the 
CXCL9(74-103) peptide alone, which suggests that DENV E DIII is unable to bind to heparin and only 
the CXCL9(74-103) peptide is bound (Figure 8A). Even when a ten-fold lower concentration of the 
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peptide (40 nM) is injected with DENV E DIII (400 nM), the peptide was still able to block the binding 
of DENV E DIII to heparin completely (Figure 8B). At a 100-fold molar excess of DENV E DIII (400 nM) 
over CXCL9(74-103) (4 nM), an increased resonance signal was measured when compared to binding 
of the peptide alone, which suggests binding of DENV E DIII to the immobilized heparin (Figure 8C). 
However, the binding curve at 4 nM CXCL9(74-103) plus DENV E DIII did not yet coincide with the curve 
of DENV E DIII in the absence of CXCL9(74-103), which indicates that the peptide is still able to partially 
block DENV E DIII binding. In contrast, CXCL9(86-103) could only moderately inhibit DENV E DIII binding 
when it was injected at equimolar concentrations (Figure 8D), whereas at 10-fold lower concentrations 
of CXCL9(86-103) the inhibition was completely abrogated (Figure 8E). 
4. Discussion 
In addition to their role in leukocyte migration during inflammation and infection, a number of 
chemokine ligands have been reported to have antibacterial, antifungal or parasiticidal activity 
independent of any interaction with their proper GPCRs [57-61]. One of the most potent 
chemoattractants with such direct antimicrobial activity is the CXC chemokine CXCL9 [58;62;63]. Upon 
infection, mononuclear cells, fibroblasts, endothelial and epithelial cells are stimulated by interferons 
to produce the CXC chemokine receptor 3 (CXCR3) ligands CXCL9, CXCL10 and CXCL11 [64;65]. Co-
stimulation of these cells with interferons and microbial compounds such as toll-like receptor ligands 
may result in the production of large amounts of CXCL9 and CXCL10, i.e. µg levels of chemokine 
produced per 106 cells. CXCL9 and CXCL10 exert direct antibacterial effects that are comparable to the 
effects mediated by cationic antimicrobial peptides, like defensins [58]. The interferon-induced ligands 
for CXCR3 have also been reported to be important for the response to viral infections [66]. The 
importance of chemokines in antiviral defense is underscored by the existence of viral mimicry of the 
chemokine network including virally encoded seven transmembrane receptors which bind chemokines 
and allow viruses to escape from an efficient immune response [67]. CXCR3 is present on activated T 
cells and NK cells and therefore is an important receptor for the migration of these cells to sites of 
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infection. In general the effect of the CXCR3 ligands on lymphocyte and NK cell migration is thought to 
explain their crucial role in the antiviral response. CXCL9 is an exception in the chemokine family since 
it has a COOH-terminal sequence extension not present in other CXCR3 ligands but conserved across 
species. Recently, we observed that this COOH-terminal tail which contains mainly lysine residues is 
partially or completely removed from most of the natural CXCL9 proteins isolated from fibroblast or 
leukocyte cultures treated with inflammatory stimuli [44]. These COOH-terminally truncated CXCL9 
proteins retain their CXCR3-dependent signaling properties in vitro [68]. Thus, the extended COOH-
terminal sequence is not crucial for its GPCR-dependent signaling properties.  
In addition to their interaction with GPCRs, chemokines are known to bind to heparin and other GAGs 
[22;40;41]. Although mutations in the chemokine GAG binding domains do not affect the interaction 
of chemokines with their specific GPCRs, these strongly reduce the in vivo chemotactic activity of 
chemokines [38;69;70]. In addition to CXCL9, CXCL12γ, a ligand for CXCR4, also has an extremely 
positively charged COOH-terminal tail not present in other chemokines. In this manuscript we 
demonstrate that peptides derived from the CXCL9 and CXCL12 COOH-terminal sequences bind to 
GAGs with high affinity. GAGs on cellular HSPGs are not only present to prevent wash-out of 
chemokines on the endothelial layer of blood vessels but HSPGs are also used as (co-)receptor for 
attachment and/or entry by different viruses. Therefore, the interference with the viral attachment 
process is considered an attractive antiviral strategy [71;72]. Such antiviral compounds might be used 
to combat several unrelated viral infections. Also, it has been suggested that less resistance to such 
antivirals due to viral mutations can occur [2;8;33]. Many polyanions, as GAG mimicking agents, have 
been developed and evaluated to bind viruses, although the clinical use of these compounds has been 
limited because of the anticoagulant side-effects [72]. Alternatively, positively charged molecules that 
bind to cell surface-associated HSPGs may block viral attachment and infection [34]. Therefore, we 
evaluated the ability of several positively charged COOH-terminal chemokine-derived peptides to 
inhibit the replication of HSPG-binding viruses. We recently showed that intravenous injection of up 
to 100 µg of such peptides in mice did not lead to toxicity [44]. The COOH-terminal peptides derived 
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from CXCL9 (30 amino acid-, 20 amino acid- and 18 amino acid-long) and CXCL12γ (31 amino acid- and 
22 amino acid-long), which were tested in this study, have a pI of >11 and >12, respectively, 
comparable to the previously reported 20 amino acid-long synthetic anti-LPS peptides which also have 
a pI of >11 [33]. All chemokine-derived peptides tested in our study, with the exception of CXCL9(86-
103) and CXCL9(74-86), bound with high affinity to immobilized heparin and cell-bound HS, which 
mimics GAGs on the target cells for HSPGs binding viruses. This could be explained by the presence of 
GAG binding motifs (BBXB and XBBBXXBX) in the peptides in which B is a positively charged amino acid. 
Indeed, CXCL9(74-103) and CXCL9(74-93) contain 2 typical GAG binding motifs between Lys-75 and 
Lys-78, and between Lys-85 and Lys-89, and were found to bind heparin with an affinity approximately 
260-fold and 75-fold higher compared to CXCL9(86-103), which lacks the 2 GAG binding motifs. 
Although CXCL9(79-103) and CXCL9(74-86) contain 1 GAG binding motif (between Lys-85 and Lys-89 
or Lys-75 and Lys-78, respectively), their affinity for heparin was found to be approximately 50-fold or 
1200-fold lower compared to CXCL9(74-103). Two COOH-terminal CXCL12γ peptides tested in this 
study, i.e. CXCL12γ(68-98) and CXCL12γ(77-98), both containing 2 typical GAG binding motifs between 
Lys-77 and Lys-80, and between Lys-84 and Lys-88, displayed comparable heparin binding affinities 
which was reflected by the ability to inhibit viral infection. It seems that the presence of 2 GAG binding 
motifs is necessary for potent GAG interactions and the resulting antiviral activity. The low affinity of 
CXCL9(74-86) for heparin shows that not only the presence of GAG binding motifs, but also the length 
of the peptide is important. The CXCL9(74-93) peptide, which is only 7 amino acids longer than 
CXCL9(74-86), shows a much higher affinity for heparin. In addition, CXCL9(86-103) does not contain 
any consensus GAG binding motif but still shows 4-fold higher affinity for heparin than CXCL9(74-86). 
Except for CXCL9(86-103) and CXCL9(74-86), all tested COOH-terminal peptides exerted antiviral 
activity against RSV, HSV-1 and DENV-2 with EC50 values ranging from 9 µM to 115 µM but were less 
or not active against HSV-2, VV, ADV-2. Although HS serves as an initial attachment site for both HSV-
1 and HSV-2, remarkably less antiviral activity against HSV-2 was found. Even against different clinical 
isolates of HSV-1 and HSV-2, the same trend was observed. Such different antiviral activities are not 
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exceptional since even in the case of different serotypes of one HSV, specific recognition of different 
HS structures has been reported [73]. Also, differences in diversity, substitution rates and 
recombination rates between HSV-1 and HSV-2 glycoproteins were observed [74]. It can be suggested 
that HSV-2, ADV-2 and VV may use different GAGs as co-receptors for entering and infecting the host 
cells. If the peptides show lower affinity for the most important GAGs for a specific virus, one could 
presume that they have lower antiviral activity. Recently, it was already described that CXCL9(74-103) 
binds with high but different affinity to GAGs [44]. This specificity is mostly determined by the GAG 
binding motifs of the peptide. Another potential explanation for the difference in antiviral activity 
against these viruses is the importance of GAGs as co-receptors. It is possible that some viruses are 
more dependent on GAGs for infecting cells than others. Finally, anti-DENV-2 activity was further 
investigated and SPR analysis showed that CXCL9(74-103) was a very strong competitor for the binding 
of DENV E DIII to heparin. 
In cell cultures, no toxic effect was detected with the chemokine-derived peptides up to concentrations 
of 150 µM. In addition, no effect of the peptides on either spontaneous or virus-induced production 
of cytokines such as IFN-β or on the activation of caspase-1 was observed. In view of this, the peptides 
derived from the natural COOH-terminal sequences of CXCL9 and CXCL12γ might be lead molecules 
for the generation of antiviral drugs that block the entry of viruses such as HSV-1, RSV and DENV-2 by 
binding to GAGs on target cells. The potency of these antiviral peptides may be increased by alternative 
formulations, as demonstrated for peptide-derived dendrimers [75-78]. As it is known that other 
viruses such as herpesviruses (e.g. cytomegalovirus, varicella-zoster virus, Epstein-barr virus), hepatitis 
viruses (e.g. HBV, HCV, HDV), HIV and human papillomavirus use HS as a (co-)receptor for entry, 
antiviral activity of the chemokine peptides could be tested against these viruses. Our observation also 
means that CXCL9 and CXCL12 may not only be important for the antiviral response due to their 
chemoattractant properties for activated T cells and NK cells but in addition directly inhibit viral 
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Table 1. Affinity data of the binding of CXCL9 and CXCL12γ peptides to heparin 
 COOH-terminal peptide KD (nM) A 
 CXCL9(74-103) 3.1 ± 1.3 
 Acetyl-CXCL9(74-103)-amide 8.8 ± 5.0 
 CXCL9(86-103) 820 ± 240 
 CXCL9(79-103) 162 ± 23 
 CXCL9(74-93) 11 ± 4.8 
 CXCL9(74-86) 3558 ± 792 
 CXCL12γ(68-98) 8.0 ± 0.3 
 CXCL12γ(77-98) 18 ± 1.5 
A Data are the mean (±SD) of at least three independent experiments. KD: binding affinity was calculated 




Table 2. Antiviral activity of the COOH-terminal peptides  
EC50 A (µM) 
COOH-terminal peptide ADV-2 DENV-2 HSV-1 HSV-2 RSV VV
CXCL9(74-103) >100 11 ± 4 15 ± 10 >100 23 ± 0 >100
Acetyl-CXCL9(74-103)-amide >100 21 ± 4 9 ± 7 >100 31 ± 11 >100
CXCL9(86-103) >100 >100 >100 >100 >100 >100 
CXCL9(79-103) >100 >100 33.5 ± 9 >100 100 >100
CXCL9(74-93) >100 43 ± 13 14 ± 14 >100 50 ± 1 >100
CXCL9(74-86) >100 >100 >100 >100 >100 >100
CXCL12γ(68-98) >100 22 ± 3 39 ± 14 >100 115 ± 2 >100
CXCL12γ(77-98) >100 48 ± 21 59 ± 15 >100 109 ± 12 >100 
A 50 % effective concentration, required to reduce virus-infected cytopathogenicity or the number of 
infected cells by 50 %. Data shown are the mean (± SD) of three independent experiments. ADV: 
adenovirus, DENV: dengue virus, HSV-1: herpes simplex virus type 1 (KOS strain), HSV-2: herpes 





Figure 1. Overview of the synthesized COOH-terminal peptides of CXCL9 and CXCL12γ 
The theoretical pI, Mr and experimentally determined Mr are listed. For clarity, basic amino acids were 





Figure 2. Synthesis of COOH-terminal peptides of CXCL12γ 
The chemokine-derived COOH-terminal peptides CXCL12γ(68-98) and NH2-terminally site-specifically 
biotinylated CXCL12γ(68-98) were chemically synthesized based on Fmoc-chemistry. The averaged 
mass spectra of purified CXCL12γ(68-98) [panel A] and biotinylated CXCL12γ(68-98) [panel B] are 
shown. The deconvoluted experimentally determined mass spectra indicating the Mr of the COOH-





Figure 3. Surface plasmon resonance (SPR) analysis of the interaction between COOH-terminal 
peptides of CXCL9 and CXCL12γ and heparin. 
Sensorgrams show the binding of different concentrations of CXCL9(74-103) [A], acetyl-CXCL9(74-103)-
amide [B], CXCL9(74-93) [C], CXCL9(79-103) [D], CXCL9(86-103) [E], CXCL9(74-86) [F], CXCL12γ(68-98) 
[G] and CXCL12γ(77-98) [H] to immobilized heparin. The binding curves of 0 to 120 sec show the 
association, whereas those of 120 to 300 sec show the dissociation phase. The y-axis indicates the 





Figure 4. Binding of COOH-terminal peptides to cellular GAGs 
Dose-dependent binding of NH2-terminally biotinylated CXCL9(74-103) and CXCL12γ(68-98) to CHO 
cells was assessed by flow cytometric analysis (panel A). The y-axis shows the fluorescence intensity of 
streptavidin-allophycocyanin. Panel B shows the binding of biotinylated CXCL12γ(68-98) to CHO cells 
treated or not treated with sodium chlorate (NaClO3). Treatment with NaClO3 reduces the expression 
of GAGs so that binding of the COOH-terminal peptides was ensured to be GAG-mediated. Statistical 
comparison to evaluate the binding of biotinylated peptides on cells treated or not treated with NaClO3 





Figure 5. Antiviral activity of the COOH-terminal peptides against clinical isolates of HSV-1 and HSV-2  
Antiviral activity against HSV-1 KOS strain, HSV-2 G strain and clinical isolates of wild-type HSV-1 (RV-
852, RV-849, RV-832, RV-830) and HSV-2 (RV-795, RV-723, RV-720, RV-636) were determined on HEL 





Figure 6. Effect of the COOH-terminal peptides on the activation of caspase-1 and evaluation of the 
expression of heparan sulfate (HS) in HEL and HeLa cells 
The activation of caspase-1 was determined in HEL (A), HeLa (B) and HMEC-1 cells (C). Therefore cells, 
treated with vehicle [filled circles], 25 µM CXCL9(74-103) [filled square) or CXCL9(86-103) [filled 
triangles], were lysed and incubated with the caspase-1 substrate Ac-YVAD-AMC. Fluorescence 
intensity was measured for 4 h (C) or 10 h (A, B) to visualize caspase-1-dependent Ac-YVAD-AMC 
cleavage. Data originate from one representative experiment out of two and are the mean (± SEM) of 
the fluorescence intensity of 3 independent cell lysates. Panel D shows the expression of HS on HEL 
and HeLa cells as assessed by staining cells with a specific mouse monoclonal anti-human HS antibody 




Figure 7. Dose-dependent anti-DENV-2 activity of CXCL9 or CXCL2γ peptides in endothelial cells and 
immunofluorescent staining of DENV-2 
HMEC-1 cells were infected with DENV-2 in the presence of different concentrations of CXCL9 (panel 
A, upper) or CXCL12γ peptides (panel A, lower). Viral infectivity was quantified 24 h after infection by 
flow cytometry using an anti-DENV-2 specific antibody. Data represent the percentage of infected cells 
relative to the virus control. The mean (+ SD) of three independent experiments is shown (panel A). 
Panel B shows immunofluorescent staining of DENV-2 attachment to HMEC-1 cells. HMEC-1 cells were 
incubated with DENV-2 in the presence or absence of 20 µM TAMRA-labeled CXCL9(74-103). Next, the 
nuclei (blue) and DENV-2 particles (green) were stained with Hoechst 33342 or a mouse anti-dengue 




Figure 8. Surface plasmon resonance (SPR) analysis of the competition between CXCL9 peptides and 
DENV E domain III for binding to heparin 
Sensorgrams show the binding of DENV envelope protein domain III (E DIII) to heparin in the presence 
(blue) or absence (red) of different concentrations of the CXCL9(74-103) (A-C) and CXCL9(86-103) (D, 
E) peptides. The binding of CXLC9 peptides in the absence of DENV E DIII is shown in green. The binding 
curves of 0 to 120 sec show the association, whereas those of 120 to 300 sec show the dissociation 
phase. The y-axis indicates the resonance signal as shown in resonance units (RU).  
 
